Evolus, Inc.

NasdaqGM EOLS

Evolus, Inc. Free Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2024: USD -23.39 M

Evolus, Inc. Free Cash Flow is USD -23.39 M for the Trailing 12 Months (TTM) ending September 30, 2024, a 85.03% change year over year. Free cash flow is the amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.

Evolus, Inc. Free Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -156.29 M, a -79.39% change year over year.
Evolus, Inc. Free Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -87.12 M, a -216.93% change year over year.
Evolus, Inc. Free Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -27.49 M, a 63.59% change year over year.
Evolus, Inc. Free Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2020 was USD -75.51 M, a 18.72% change year over year.

Key data

Date	Free Cash Flow	Operating Cash Flow	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities

NasdaqGM: EOLS

Evolus, Inc.

CEO	Mr. David Moatazedi
IPO Date	Feb. 8, 2018
Location	United States
Headquarters	520 Newport Center Drive
Employees	322
Sector	Consumer Discretionary
Industries Cosmetics Biotechnology Pharmaceuticals

Description

Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

Key trends

Past 5 years